

What is claimed is:

- 1 1. A pharmaceutical composition for oral administration which comprises a core tablet of
2 cefuroxime axetil inside a capsule.
- 1 2. The composition according to Claim 1, wherein the tablet is in the shape of a capsule
2 (caplet).
- 1 3. The composition according to Claim 2, wherein the smallest dimension of the caplet is
2 greater or equal to 65% of the internal diameter of the capsule.
- 1 4. The composition according to Claim 3, wherein the smallest dimension of the caplet is
2 greater or equal to 75% of the internal diameter of the capsule.
- 1 5. The composition according to Claim 4, wherein the smallest dimension of the caplet is
2 greater or equal to 80% of the internal diameter of the capsule.
- 1 6. The composition according to Claim 1, wherein the core tablet contains more than 10%
2 w/w of a disintegrant.
- 1 7. The composition according to Claim 6, wherein the core tablet contains more than 15%
2 w/w of a disintegrant.
- 1 8. The composition according to Claim 7, wherein the core tablet contains more than 20%
2 w/w of a disintegrant.
- 1 9. The composition according to Claims 6, 7, and 8, wherein the disintegrant is selected
2 from microcrystalline cellulose, starch, croscarmellose, crospovidone, sodium
3 starch glycolate, and combinations thereof.
- 1 10. The composition according to Claim 1, wherein the cefuroxime axetil is substantially
2 amorphous.
- 1 11. The composition according to Claim 1, wherein the capsule is a two-piece hard gelatin
2 capsule.

1 12. The composition according to Claim 1, wherein the capsule is a two-piece
2 hydroxypropylmethylcellulose capsule.

1 13. The composition according to Claim 1, wherein the capsule is a two-piece capsule
2 made of vegetable or plant-based cellulose.

1 14. The composition according to Claim 1, wherein the capsule is a two-piece capsule
2 made of polysaccharide.